Avantyo Newsletter My account Search Calendar
Next: Clinical Trials Symposium on 18th November, 2022

Dr. Eugen Bujor Almasan is the new interim president of Competent Authority (NAMMDR)

Back to all news

Dr. Eugen Bujor Almasan is the new interim president of Competent Authority (NAMMDR)

The new interim president of NAMMDR was appointed by the Ministry of Health on 20th of May 2020, after being a vice-president for a few months and personal adviser to a health secretary of state in 2019. Dr. Almasan has also occupied top positions in the industry of clinical research, as IQVIA director and first president of the Romanian CROs’ Association (ACCSCR).

In 2020, the president position of the National Agency of Medicine and Medical Devices in Romania (NAMMDR) has been temporarily exercised by Roxana Stroe, appointed in January, while Dr. Almasan was vice-president. The spokesperson of the Ministry of Health, Oana Grigore, has declared to HotNews.ro, that the position of president of the National Medicines Agency was vacant now.

Dr. Almasan has run for vice-presidency during the competition for the top positions of NAMMDR, scheduled for 6th of November 2019 but postponed for subsequent dates after the Romanian Government has been changed. In January 2020, he was appointed as vice-president.

The National Agency of Medicine and Medical Devices in Romania (NAMMDR) is the national competent authority for clinical trials in our country, together with the National Commission for Bioethics of Medicines and Medical Devices in Romania.

Recently, Dr. Almasan has participated on behalf of NAMMDR, together with other three colleagues, as a special guest in the roundtable organized by AVANTYO Institute of Clinical Research on Friday, May 15, with the theme “Development of Clinical Trials during pandemic COVID 19 period”.

AVANTYO Institute of Clinical Research has taken the initiative to organize this roundtable with the purpose to bring altogether around one table, the representatives of the competent authorities and the pharmaceutical companies & contract research organizations, in order to facilitate the improvement of the clinical trials approval process in Romania and enhance the communication between representatives of NAMMDR and the industry.

Posted on: 22 May 2020